

### **AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions and listings of claims in the application.

#### **Listing of Claims**

1.-9. (Canceled)

10. (Previously Presented) An antisense oligonucleotide against SMAD7 comprising SEQ ID No 15: 5'-ZTXGCCCTTCTCCCXGCAZC-3', wherein X is 5-methyl 2'-deoxycytidine 5'-monophosphate and Z is 2'- deoxyguanosine methylphosphonate, or the complementary sequence thereto.

11.-19. (Canceled)

20. (Previously Presented) A composition comprising the antisense oligonucleotide of claim 10 and a pharmaceutically acceptable excipient.

21. (Withdrawn) A method of treating inflammatory bowel disease, comprising administering to a patient in need thereof a pharmaceutically acceptable amount of the antisense oligonucleotide of claim 10.

22. (Canceled)

23. (Withdrawn) A method of treating Crohn's disease or ulcerative colitis, comprising administering to a patient in need thereof a pharmaceutically acceptable amount of the antisense oligonucleotide of claim 10.

24. (Canceled)

25. (Withdrawn) The method of claim 23, wherein the antisense oligonucleotide is administered orally.

26. (Currently Amended) The antisense oligonucleotide of claim 10 wherein at least one additional internucleoside linkage is a methylphosphonate linkage.

27. (Currently Amended) The antisense oligonucleotide of claim 10 wherein the oligonucleotide comprises at least one additional methylphosphonate linkage and at least one phosphorothioate linkage.

28. (Previously Presented) The antisense oligonucleotide of claim 10 wherein 2'-deoxyribonucleotides are replaced by corresponding ribonucleotides.

29. (Previously Presented) The antisense oligonucleotide of claim 10 wherein the oligonucleotide comprises up to 21 nucleotides in length.